WuXi Biologics Achieves Record Wins at 2026 Asia-Pacific Biopharma Excellence Awards
WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), recently made notable strides at the 2026 Asia-Pacific Biopharma Excellence Awards. The company earned six prestigious awards along with two individual recognitions, marking a historic achievement as the first organization to garner this volume of accolades in a single event. The awards highlight WuXi Biologics' consistent excellence in the realms of biotherapeutics development, manufacturing efficiency, and digital innovation.
The honors received by WuXi Biologics include the titles of Best Contract Development and Manufacturing Organization, Best Aseptic Fill-Finish Packaging CMO of the Year, and Excellence in Bioprocessing Automation and Digitalization. This impressive range of awards validates the company's unwavering commitment to providing high-quality and innovative biopharmaceutical solutions.
Dr. Sherry Gu, the company’s Chief Technology Officer and Executive Vice President, received the distinguished award of CTO of the Year for her leadership and vision in advancing biologics development. Additionally, Dr. Jeremy Guo, Senior Vice President and Head of Global Drug Product Operations, was honored with the title of Head of Fill-Finish and Formulation of the Year, emphasizing his dedication to ensuring reliable drug product manufacturing.
Dr. Chris Chen, CEO of WuXi Biologics, expressed gratitude for this recognition, stating, "We are honored to receive such a significant number of awards at the 2026 Asia-Pacific Biopharma Excellence Awards. These accolades reflect the trust our global partners place in us, the expertise of our dedicated team, and our continuous pursuit of operational excellence and innovation. Our ongoing endeavors aim not only to enhance our integrated CRDMO platform but also to improve digital bioprocessing capabilities to fast-track our partners' innovative therapies to patients globally."
WuXi Biologics continues to solidify its reputation as a partner of choice for biopharma innovators and multinational enterprises. With an extensive portfolio of 945 integrated projects, the company boasts one of the largest collections of complex biologics globally. Approximately half of these projects involve advanced formats such as bi-specific and multi-specific antibodies as well as Antibody-Drug Conjugates (ADCs).
To further diversify its services, WuXi Biologics implemented cutting-edge technology solutions to expedite timelines, enhance quality, and ensure scalable production. The firm's WuXia™ TrueSite platform, which allows for a targeted integration-based CHO cell line model, has achieved remarkable antibody titers exceeding 8.0 g/L while maintaining expression stability throughout 60 generations.
Moreover, WuXi Biologics has advanced its technologies for high-dose delivery systems now utilized in clinical and commercial applications. Their high-throughput formulation development platform, WuXiHigh™, facilitates protein concentrations reaching up to 230 mg/mL and effectively reduces viscosity by as much as 90%. The company's commitment to manufacturing excellence is demonstrated through a flawless track record, boasting a 100% success rate in Process Performance Qualification (PPQ) campaigns since 2017.
Regulatory compliance remains another core strength of WuXi Biologics. By the end of 2025, the organization successfully passed 46 regulatory inspections, achieving a perfect score in FDA Pre-License Inspections (PLI). The company currently operates 15 GMP-certified facilities across its global network and has secured 136 facility license approvals while maintaining a 100% success rate for GMP inspections. These attributes reinforce WuXi Biologics' status as a trusted partner in the biopharmaceutical space.
In addition to its dedication to excellence in manufacturing, the company is pioneering digital innovations in biologics research. The integration of digital technologies across all facets of research, development, manufacturing, and customer interactions enables faster timelines, enhanced quality assurance, and improved transparency for stakeholders. For instance, their Electronic Batch Record (EBR) system has led to nearly a 40% increase in productivity and maintained consistent data integrity. Furthermore, WuXi Biologics has introduced the innovative digital twin platform, PatroLab™, designed to improve overall process performance and risk mitigation for biologics manufacturing.
The Asia-Pacific Biopharma Excellence Awards, hosted by IMAPAC, celebrate exceptional innovations and operational benchmarks within the biopharmaceutical sector, highlighting influential organizations and technologies that shape the future of the industry. As WuXi Biologics contributes to this landscape, its dedication to sustainable practices and commitment to environmentally friendly initiatives underscore its vision of creating shared value across the entire biopharmaceutical supply chain.
For further insights about the groundbreaking work and initiatives by WuXi Biologics, please visit their official website at www.wuxibiologics.com.
The honors received by WuXi Biologics include the titles of Best Contract Development and Manufacturing Organization, Best Aseptic Fill-Finish Packaging CMO of the Year, and Excellence in Bioprocessing Automation and Digitalization. This impressive range of awards validates the company's unwavering commitment to providing high-quality and innovative biopharmaceutical solutions.
Dr. Sherry Gu, the company’s Chief Technology Officer and Executive Vice President, received the distinguished award of CTO of the Year for her leadership and vision in advancing biologics development. Additionally, Dr. Jeremy Guo, Senior Vice President and Head of Global Drug Product Operations, was honored with the title of Head of Fill-Finish and Formulation of the Year, emphasizing his dedication to ensuring reliable drug product manufacturing.
Dr. Chris Chen, CEO of WuXi Biologics, expressed gratitude for this recognition, stating, "We are honored to receive such a significant number of awards at the 2026 Asia-Pacific Biopharma Excellence Awards. These accolades reflect the trust our global partners place in us, the expertise of our dedicated team, and our continuous pursuit of operational excellence and innovation. Our ongoing endeavors aim not only to enhance our integrated CRDMO platform but also to improve digital bioprocessing capabilities to fast-track our partners' innovative therapies to patients globally."
WuXi Biologics continues to solidify its reputation as a partner of choice for biopharma innovators and multinational enterprises. With an extensive portfolio of 945 integrated projects, the company boasts one of the largest collections of complex biologics globally. Approximately half of these projects involve advanced formats such as bi-specific and multi-specific antibodies as well as Antibody-Drug Conjugates (ADCs).
To further diversify its services, WuXi Biologics implemented cutting-edge technology solutions to expedite timelines, enhance quality, and ensure scalable production. The firm's WuXia™ TrueSite platform, which allows for a targeted integration-based CHO cell line model, has achieved remarkable antibody titers exceeding 8.0 g/L while maintaining expression stability throughout 60 generations.
Moreover, WuXi Biologics has advanced its technologies for high-dose delivery systems now utilized in clinical and commercial applications. Their high-throughput formulation development platform, WuXiHigh™, facilitates protein concentrations reaching up to 230 mg/mL and effectively reduces viscosity by as much as 90%. The company's commitment to manufacturing excellence is demonstrated through a flawless track record, boasting a 100% success rate in Process Performance Qualification (PPQ) campaigns since 2017.
Regulatory compliance remains another core strength of WuXi Biologics. By the end of 2025, the organization successfully passed 46 regulatory inspections, achieving a perfect score in FDA Pre-License Inspections (PLI). The company currently operates 15 GMP-certified facilities across its global network and has secured 136 facility license approvals while maintaining a 100% success rate for GMP inspections. These attributes reinforce WuXi Biologics' status as a trusted partner in the biopharmaceutical space.
In addition to its dedication to excellence in manufacturing, the company is pioneering digital innovations in biologics research. The integration of digital technologies across all facets of research, development, manufacturing, and customer interactions enables faster timelines, enhanced quality assurance, and improved transparency for stakeholders. For instance, their Electronic Batch Record (EBR) system has led to nearly a 40% increase in productivity and maintained consistent data integrity. Furthermore, WuXi Biologics has introduced the innovative digital twin platform, PatroLab™, designed to improve overall process performance and risk mitigation for biologics manufacturing.
The Asia-Pacific Biopharma Excellence Awards, hosted by IMAPAC, celebrate exceptional innovations and operational benchmarks within the biopharmaceutical sector, highlighting influential organizations and technologies that shape the future of the industry. As WuXi Biologics contributes to this landscape, its dedication to sustainable practices and commitment to environmentally friendly initiatives underscore its vision of creating shared value across the entire biopharmaceutical supply chain.
For further insights about the groundbreaking work and initiatives by WuXi Biologics, please visit their official website at www.wuxibiologics.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.